Progress of detection and clinical application of minimal residual disease in multiple myeloma

VernacularTitle:多发性骨髓瘤微小残留病检测及临床应用新进展
Author: Xiaotong CHEN ¹ ; Yingjun CHANG
Author Information

1. 北京大学人民医院血液科　北京大学血液病研究所　国家血液系统疾病临床医学研究中心　造血干细胞移植治疗血液病北京市重点实验室，北京　100044
Keywords: Multiple myeloma; Minimal residual disease; Second-generation sequencing; Multiparameter flow cytometry; Recurrence; Prognosis
From: Journal of Leukemia & Lymphoma 2024;33(11):700-704
CountryChina
Language:Chinese
Abstract: Multiple myeloma (MM) is a common haematologic malignancy which remains incurable. With the development of novel drugs, 80% of patients can achieve complete remission with induction therapy. Minimal residual disease (MRD) can not only be used for predicting outcomes, but also can be used as a surrogate endpoint in clinical trials. This article reviews the recent progress in MRD detection techniques, detection time points, sample selection, and MRD in forecasting prognosis and guiding individual therapy of patients with MM.